RESUMO
Administration of an immunomodulator, galavit, for stage II-III non-small lung cancer along with standard therapy was followed by immunological vigor improvement by the end of the course. CD3, CD4, IgA, IgM and IgG indices were normal in more than 80% of the study group by day 51 after surgery; CD8, CD20 and HLA-DR--in more than 50%; CD16--in 45.2%. In control, by day 51, normal IgG and HLA-DR levels were reported in 60%. The remaining indices were normal in less than 50%. Our results point to immunological vigor improvement due to use of galavit. The drug is well tolerated, has neither side effects nor toxicity.
Assuntos
Antígenos de Neoplasias/sangue , Carcinoma Pulmonar de Células não Pequenas/imunologia , Fatores Imunológicos/uso terapêutico , Neoplasias Pulmonares/imunologia , Ftalazinas/uso terapêutico , Adulto , Idoso , Antígenos CD20/sangue , Complexo CD3/sangue , Antígenos CD4/sangue , Antígenos CD8/sangue , Carcinoma Pulmonar de Células não Pequenas/patologia , Método Duplo-Cego , Feminino , Antígenos HLA-DR/sangue , Humanos , Imunoglobulina A/sangue , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Fatores Imunológicos/farmacologia , Luminol/análogos & derivados , Neoplasias Pulmonares/patologia , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Ftalazinas/farmacologia , Receptores de IgG/sangueRESUMO
The article deals with the method and results of ultrasonically-guided fine needle percutaneous biopsy performed in 45 patients for differential diagnosis of cancer of the pancreas. Thirty-four patients had tumors of the pancreas, 10--chronic indurative pancreatitis, one patient had a cyst. The diagnosis was verified morphologically in 34 patients: in 25 of 31 patients with primary tumors of the pancreas and in 9 of 11 patients with chronic pancreatitis and a cyst. The method is safe, highly informative and allows the character and nature of the pancreatic tumor to be determined precisely and the tactics of special treatment to be thus elaborated.
